BARRIER CONTRACEPTION FOR PREVENTION OF STD

此次采购将产生一项多个分支机构的观察性研究 使用不同屏障避孕方案的妇女预防 以下性传播疾病(性病)：淋病和 衣原体。这项研究将确定最大可能的保护 防止性传播疾病提供始终如一和正确的 使用屏障避孕药。次要目标端点将是 其他性传播疾病和怀孕的发生 在研究过程中检测到。研究设计将包括一个教育性的 和激励部分，以确保足够数量的 持续高水平使用障碍物的参与者。因为 决定采用个人性质的障碍方法，进行教育 激励性干预将针对所有研究参与者， 受试者将选择他们将使用的方法(或不使用方法 在随访期内。典型的控制组将不存在， 控制措施是选择不使用屏障的干预招募人员 方法在研究过程中。这项研究将确定： (1)各种屏障避孕方法的最大程度， 单独使用或联合使用可保护女性免受感染 淋病奈瑟菌和沙眼衣原体； (2)通过以下方式预防其他性传播疾病和怀孕的证据 在接诊过程中持续正确使用屏障避孕药 学习； (3)失败的相关因素(即不使用、不当使用、避孕套 破损或滑移、其他方法故障)； (4)使用化学或物理屏障造成的局部毒性 避孕方法。

This procurement will produce a multiple arm observational study of women using various barrier contraceptive regimens for the prevention of the following sexually transmitted diseases (STDs): gonorrhoea and chlamydia. This study will determine the maximum possible protection against sexually transmitted diseases provided by consistent and correct use of barrier contraceptives. Secondary endpoints of interest will be the occurrence of other sexually transmitted diseases and pregnancy as detected during the study. The study design will include an educational and motivational component in order to assure an adequate number of participants with continued high levels of barrier use. Because of the personal nature of the decision to use a barrier method, the educational and motivational intervention will be aimed at all study participants, and subjects will choose which method (or no method) they will use during the follow-up period. A typical control group will not exist, the controls being intervention recruits who choose not to use a barrier method during the study. The study will determine: (1) the maximum extent to which various barrier contraceptive methods, used individually or in combination, can protect women from infection with Neisseria gonorrhoea and Chlamydia trachomatis; (2) evidence for the prevention of other STDs and pregnancy by consistent and proper barrier contraceptive use during the course of the study; (3) the correlates of failure (i.e. nonuse, improper use, condom breakage or slippage, other method failure); (4) local toxicity attributable to use of chemical or physical barrier contraceptive methods.